Note 7 - Collaborative Agreements	6 Months Ended
Jun. 30, 2017
In Process Research and Development [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7 - COLLABORATIVE AGREEMENTS The Company and the University of Toronto (the “University”), a stockholder of the Company, entered into an agreement effective December 14, 2004 ( the “Research Agreement”) for the performance of a research project titled “Evidence for existence of Teneurin C-terminal Associated Peptide (“TCAP”) receptors in neurons” (the “Project”). The Research Agreement expired on March 31, 2013. The Company and the University entered into a new agreement effective April 1, 2014 ( the “New Research Agreement”) for the performance of a research project titled “TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The purpose of the New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the “Professor”) in regard to TCAP mediated stress attenuation in vertebrates. In connection to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. In February 2017, the term of the New Research Agreement was extended to December 31, 2017, which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made. The University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a 10 -year period which ends on April 1, 2022. The Professor has been granted 483,299 stock options, of which 275,000 are fully vested, at an exercise price of $1.00 exercisable over 10 or 13 year periods from the date of grant, which end on either March 30, 2021, December 1, 2022, April 15, 2026 or March 1, 2027. The sponsorship research and development expenses pertaining to the Research Agreements were $20,233.34 and $3,000 for the periods ended June 30, 2017 and 2016, respectively.

NOTE

COLLABORATIVE AGREEMENTS

The Company and the University of Toronto (the “University”), a stockholder of the Company, entered into an agreement effective

December 14, 2004 (

the “Research Agreement”) for the performance of a research project titled “Evidence for existence of Teneurin C-terminal Associated Peptide (“TCAP”) receptors in neurons” (the “Project”). The Research Agreement expired on

March 31, 2013.

The Company and the University entered into a new agreement effective

April 1, 2014 (

the “New Research Agreement”) for the performance of a research project titled “TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The purpose of the New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the “Professor”) in regard to TCAP mediated stress attenuation in vertebrates. In connection to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. In

February 2017,

the term of the New Research Agreement was extended to

December 31, 2017,

which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made.

The University has been granted

25,000

stock options which are fully vested at the exercise price of

$1.00

exercisable over a

-year period which ends on

April 1, 2022.

The Professor has been granted

483,299

stock options, of which

275,000

are fully vested, at an exercise price of

$1.00

exercisable over

year periods from the date of grant, which end on either

March 30, 2021,

December 1, 2022,

April 15, 2026

March 1, 2027.

The sponsorship research and development expenses pertaining to the Research Agreements were

$20,233.34

and

$3,000

for the periods ended

June 30, 2017

and

2016,

respectively.